Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

The antibody‐drug conjugate trastuzumab emtansine (T‐DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)–positive breast cancer. We aimed to study tumor HER2 expression and its effects on T‐DM1 responses in patients with HER2‐positive urothelial bladder cancer (UBC) or pancrea...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Elisabeth G. E., Rüschoff, Josef, Lolkema, Martijn, Tabernero, Josep, Gianni, Luca, Voest, Emile, de Groot, Derk Jan A., Castellano, Daniel, Erb, Gilles, Naab, Julia, Donica, Margarita, Deurloo, Regula, van der Heijden, Michiel S., Viale, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278525/
https://www.ncbi.nlm.nih.gov/pubmed/37119523
http://dx.doi.org/10.1002/cam4.5893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278525/
https://www.ncbi.nlm.nih.gov/pubmed/37119523
http://dx.doi.org/10.1002/cam4.5893

Ejemplares similares